ArticleCancers2022
Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- IBD-related inflammatory memory and colorectal cancer: epigenetic mechanisms and microbiome interventions.Frontiers in immunology · 2026Pooled it
- Angiogenesis in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A Prussian Blue Nanozyme-Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Investigating radiotherapy's impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab.World journal of gastrointestinal oncology · 2025Article
- Angiogenic Factors and Inflammatory Bowel Diseases.Biomedicines · 2025Review
- A bidirectional Mendelian randomization analysis of the causal relationship between inflammatory bowel disease and breast cancer based on estrogen receptor status.Discover oncology · 2024Article
- Molecular targets associated with ulcerative colitis and the benefits of atractylenolides-based therapy.Frontiers in pharmacology · 2024Review
- Contribution of Blood Vessel Activation, Remodeling and Barrier Function to Inflammatory Bowel Diseases.International journal of molecular sciences · 2023Review
- Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease.Cancers · 2022Article
- Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.Current drug metabolism · 2022Article
- Review
- Review
- Managing inflammatory bowel disease in patients receiving cancer-associated chemotherapy and beyond.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe safety of bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and digestive and nondigestive cancers is poorly documented.
methodsWe retrospectively evaluated patient records of all adult cancer patients with IBD at our institution from April 2007 to May 2016 with an update in November 2019.
resultsTwenty-seven patients with a history of IBD (Crohn's disease,
conclusionBevacizumab combined with chemotherapy is safe in cancer patients with moderately active or quiescent IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.